- The European Commission (EC) has approved BioMarin Pharmaceutical Inc's BMRN Voxzogo (vosoritide) once-daily injection to treat achondroplasia.
- The approval covers children from 2 years until growth plates are closed, which occurs after puberty when children reach final adult height.
- Voxzogo is a modified C-type natriuretic peptide (CNP) that directly downregulates fibroblast growth factor receptor 3 (FGFR3) signaling and promoting endochondral bone formation.
- The FDA's US application for Voxzogo is under review with a target action date of November 20.
- Related content: Benzinga's Full FDA Calendar
- Price Action: BMRN stock is up 6.48% at $83.98 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
